Glenmede Trust’s Galectin Therapeutics GALT Stock Holding History

Glenmede Trust’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-8,063	Closed	-$11K	–	2617
2016 Q2	$11K	Hold	8,063	–	–	﹤0.01%	2080
2016 Q1	$11K	Hold	8,063	–	–	﹤0.01%	2018
2015 Q4	$13K	Hold	8,063	–	–	﹤0.01%	1987
2015 Q3	$18K	Hold	8,063	–	–	﹤0.01%	1928
2015 Q2	$22K	Hold	8,063	–	–	﹤0.01%	1876
2015 Q1	$27K	Hold	8,063	–	–	﹤0.01%	1855
2014 Q4	$27K	Sell	8,063 -8,100	-50%	-$35.8K	﹤0.01%	1923
2014 Q3	$81K	Sell	16,163 -15,500	-49%	-$121K	﹤0.01%	1542
2014 Q2	$437K	Sell	31,663 -33,000	-51%	-$411K	﹤0.01%	913
2014 Q1	$989K	Hold	64,663	–	–	0.01%	697
2013 Q4	$522K	Hold	64,663	–	–	0.01%	838
2013 Q3	$644K	Hold	64,663	–	–	0.01%	762
2013 Q2	$274K	Buy	+64,663	New	+$265K	﹤0.01%	987

Other funds holding GALT

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Glenmede Trust's GALT Position: Q3 2016 in Review

Glenmede Trust sold out of Galectin Therapeutics (GALT) in Q3 2016, closing a stake of 8,063 shares — an estimated $11K sold.

Glenmede Trust first reported a position in GALT in Q2 2013 and held it in 13 quarters. The position peaked at $989K in Q1 2014. 46 funds tracked by Wall St. Rank hold GALT as of Q3 2016.

Glenmede Trust reported no remaining Galectin Therapeutics position as of Q3 2016 after selling out during the quarter.
Glenmede Trust sold 8,063 Galectin Therapeutics shares in Q3 2016, an estimated $11K.
Glenmede Trust first reported a position in Galectin Therapeutics in Q2 2013 and held it in 13 quarters.
Glenmede Trust's Galectin Therapeutics position peaked at $989K in Q1 2014.
46 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2016.

Based on Glenmede Trust's 13F filing for Q3 2016, filed 14 Nov 2016.